Scandion Oncology is recruiting a Financial Controller
Be our new
in a biotech company focused on developing drugs that specifically target chemotherapy resistance mechanisms.
Scandion Oncology is a young, fast developing Copenhagen-based biotechnology company with an attractive pipeline. Scandion Oncology has two programs in clinical development with our first-in-class lead compound SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.
Scandion Oncology is listed on Nasdaq First North Growth Market Stockholm.
Please read the full job description and apply if you want to join a growing and ambitious biotech company working to combat drug resistance in cancer.